AcelRx Pharmaceuticals Inc (ACRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Vincent J. Angotti
Employees:
40
351 GALVESTON DRIVE, REDWOOD CITY, CA 94063
650-216-3500

AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet. ZALVISO is a pre-programmed and patient-controlled analgesia system.

Data derived from most recent annual or quarterly report
Market Cap 39.721 Million Shares Outstanding147.114 Million Avg 30-day Volume 3.654 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.16
Price to Revenue15.2787 Debt to Equity-0.3097 EBITDA-30.273 Million
Price to Book Value0.0 Operating Margin-1302.9465 Enterprise Value14.506 Million
Current Ratio2.513 EPS Growth0 Quick Ratio2.321
1 Yr BETA 0.921 52-week High/Low 1.2 / 0.16 Profit Margin-1266.5333
Operating Cash Flow Growth13.6518 Altman Z-Score-10.1924 Free Cash Flow to Firm -33.948 Million
View SEC Filings from ACRX instead.

View recent insider trading info

Funds Holding ACRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-12:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-28:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K/A: filed on 2022-07-26:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K/A: filed on 2022-07-25:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-07-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-02:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-05-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HOFFMAN STEPHEN J

    • Director
    67,750 2022-07-15 1

    WAN MARK A

    • Director
    67,750 2022-07-15 1

    ADAMS ADRIAN

    • Director
    242,750 2022-07-15 1

    BROADFOOT JILL MARIE

    • Director
    61,500 2022-07-15 3

    ROSEN HOWARD B

    • Director
    125,250 2022-07-15 1

    AFABLE RICHARD

    • Director
    68,750 2022-07-15 1

    BOZILENKO MARINA

    • Director
    71,500 2022-07-15 1

    ANGOTTI VINCENT J. CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    1,016,919 2022-06-07 3

    DASU BADRI N CHIEF ENGINEERING OFFICER

    • Officer
    300,595 2022-03-03 3

    PALMER PAMELA P CHIEF MEDICAL OFFICER

    • Officer
    • Director
    779,261 2022-03-03 3

    ASADORIAN RAFFI CHIEF FINANCIAL OFFICER

    • Officer
    364,205 2022-03-03 2

    EDWARDS MARK G

    • Director
    281,250 2021-06-17 0

    HAMEL LAWRENCE G CHIEF DEVELOPMENT OFFICER

    • Officer
    157,564 2020-02-11 0

    HOFFMAN C STEVEN

    • Director
    0 2018-06-14 0

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS IV LP

    THREE ARCH PARTNERS III LP

    THREE ARCH ASSOCIATES IV LP

    THREE ARCH ASSOCIATES III LP

    • Director
    • 10% Owner
    0 2018-05-21 0

    SAIA JOHN G. GENERAL COUNSEL AND SECRETARY

    • Officer
    0 2018-04-16 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    No longer subject to file 2017-06-19 0

    MORRIS TIMOTHY E CHIEF FINANCIAL OFFICER

    • Officer
    0 2017-02-07 0

    MITCHELL JANE WRIGHT CHIEF LEGAL OFFICER

    • Officer
    0 2017-02-07 0

    YATRA ONLINE, INC. CHIEF FINANCIAL OFFICER

    • Officer
    0 2014-03-25 0

    SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P

    SKYLINE VENTURE MANAGEMENT IV, LLC

    FREUND JOHN GORDON

    KANEKO YASUNORI

    • 10% Owner
    • FORMER 10% HOLDER
    No longer subject to file 2014-03-07 0

    KING RICHARD

    • Director
    134,567 2014-03-02 0

    WELCH JAMES H CHIEF FINANCIAL OFFICER

    • Officer
    0 2014-02-04 0

    CHUNG DAVID CHIEF COMMERCIAL OFFICER

    • Officer
    0 2014-02-04 0

    NOHRA GUY P

    • Director
    2,507,974 2013-09-19 0

    SCHRECK THOMAS A

    • Director
    0 2012-07-24 0

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS III LP

    THREE ARCH ASSOCIATES III LP

    THREE ARCH PARTNERS L P

    THREE ARCH ASSOCIATES L P

    • Director
    • 10% Owner
    8,206,351 2012-05-29 0

    SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P

    SKYLINE VENTURE MANAGEMENT IV, LLC

    HOFFMAN STEPHEN J

    KANEKO YASUNORI

    FREUND JOHN GORDON

    • Director
    • 10% Owner
    4,418,161 2012-05-29 0

    THREE ARCH MANAGEMENT III LLC

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS III LP

    THREE ARCH ASSOCIATES III LP

    • Director
    • 10% Owner
    0 2011-02-16 0

    THREE ARCH MANAGEMENT IV, L.L.C.

    THREE ARCH ASSOCIATES IV LP

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS IV LP

    • Director
    • 10% Owner
    0 2011-02-16 0

    ACP IV, L.P.

    NOHRA GUY P

    JANNEY DANIEL

    DELEAGE JEAN

    MACK DAVID HENRY

    ACMP IV LLC

    • Director
    • 10% Owner
    8,177,073 2011-02-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    WAN MARK A - Director

    2022-07-15 19:26:03 -0400 2022-07-15 A 15,500 a 36,750 direct

    WAN MARK A - Director

    2022-07-15 19:26:03 -0400 2022-07-15 A 31,000 a 31,000 direct

    ROSEN HOWARD B - Director

    2022-07-15 19:27:49 -0400 2022-07-15 A 15,500 a 94,250 direct

    ROSEN HOWARD B - Director

    2022-07-15 19:27:49 -0400 2022-07-15 A 31,000 a 31,000 direct

    HOFFMAN STEPHEN J - Director

    2022-07-15 19:29:39 -0400 2022-07-15 A 15,500 a 36,750 direct

    HOFFMAN STEPHEN J - Director

    2022-07-15 19:29:39 -0400 2022-07-15 A 31,000 a 31,000 direct

    ADAMS ADRIAN - Director

    2022-07-15 19:31:17 -0400 2022-07-15 A 15,500 a 211,750 direct

    ADAMS ADRIAN - Director

    2022-07-15 19:31:17 -0400 2022-07-15 A 31,000 a 31,000 direct

    AFABLE RICHARD - Director

    2022-07-15 19:32:43 -0400 2022-07-15 A 15,500 a 37,750 direct

    AFABLE RICHARD - Director

    2022-07-15 19:32:43 -0400 2022-07-15 A 31,000 a 31,000 direct

    BROADFOOT JILL MARIE - Director

    2022-07-15 19:35:13 -0400 2022-07-15 A 15,500 a 30,500 direct

    BROADFOOT JILL MARIE - Director

    2022-07-15 19:35:13 -0400 2022-07-15 A 31,000 a 31,000 direct

    BOZILENKO MARINA - Director

    2022-07-15 19:33:59 -0400 2022-07-15 A 15,500 a 40,500 direct

    BOZILENKO MARINA - Director

    2022-07-15 19:33:59 -0400 2022-07-15 A 31,000 a 31,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 22:15:04 UTC -6.6398 8.9598 2100000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 21:45:04 UTC -6.5499 8.8699 2100000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 21:15:04 UTC -6.5499 8.8699 2100000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 20:45:04 UTC -6.2208 8.5408 2100000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 20:15:03 UTC -6.2208 8.5408 2100000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 19:45:04 UTC -6.2208 8.5408 2100000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 19:15:04 UTC -6.2208 8.5408 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 18:45:04 UTC -6.3606 8.6806 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 18:15:04 UTC -6.3606 8.6806 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 17:45:04 UTC -6.3606 8.6806 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 17:15:03 UTC -6.3606 8.6806 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 16:45:04 UTC -6.003 8.323 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 16:15:04 UTC -6.003 8.323 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 15:45:04 UTC -6.003 8.323 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 15:15:04 UTC -6.003 8.323 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 14:45:04 UTC -6.003 8.323 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 14:15:03 UTC -6.003 8.323 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 13:45:04 UTC -4.8765 7.1965 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 13:15:04 UTC -4.8765 7.1965 2200000
    ACELRX PHARMACEUTICALS INC ACRX 2022-08-15 12:45:04 UTC -4.8765 7.1965 2800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ACRX -2800.0 shares, $-799.4 2022-03-31 N-PORT

    Elevate your investments